An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with vires-specific CTLs

Blood

Volumn 97, Issue 4, 2001, Pages 835-843

  Gottschalk, S ^a   Ng, C Y C ^a   Perez, M ^a   Smith, C A ^a   Sample, C ^a   Brenner, M K ^a   Heslop, H E ^a   Rooney, C M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW TRANSPLANTATION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DELETION MUTANT; DISEASE COURSE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0035865742     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.4.835     Document Type: Article

References (52)

1. Adoptive immunotherapy of EBV lymphoproliferative diseases
2. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease
3. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency
4. B-cell lymphoproliferations after bone marrow transplant
5. Epstein-Barr virus and nasopharyngeal carcinoma
6. Smooth muscle tumors in children with human immunodeficiency virus infection
7. The establishment of lymphoblastoid cell lines from adult and from foetal tissue and its dependence on EBV
8. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts
9. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children
10. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation
11. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome
12. Anti-B-cell monoclonal antibody treatment of severe post-transplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
13. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
14. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
15. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
16. Post-transplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features
17. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
18. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
19. Donor T cells to treat EBV-associated lymphoma
20. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
21. Use of genemodified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation
22. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
23. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
24. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development
25. Recognition of the Epstein-Barr virus-encoded nuclear antigens, EBNA4 and EBNA6 by HLA-A11-restricted cytotoxic T lymphocytes: Implications for down-regulation of HLA-A11 in Burkitt lymphoma
26. Conserved CTL epitopes within EBV latent membrane protein 2, a potential target for CTL-based tumor therapy
27. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid lines against which they were raised
28. Multiple HLA-A11-restricted cytotoxic T lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4
29. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7
30. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBNA3
31. Five new cytotoxic T-cell epitopes identified within Epstein-Barr virus nuclear antigen 3
32. An Epstein-Barr virus-specific cytotoxic T cell epitope on A- and B-type transformants
33. Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease
34. Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma
35. T cell responses and virus evolution: Loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues
36. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukemia
37. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts
38. Patterns of reactivity of Epstein-Barr virus-specific T cells in A-type donor cultures after reactivation with autologous A- or B-type transformants
39. EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post transplant lymphoproliferative disease
40. DNA sequence and expression of the B95-8 Epstein-Barr virus genome
41. Viral subversion of the immune system
42. Identification of a cytotoxic T-lymphocyte response to the novel BARFO protein of Epstein-Barr virus: A critical role for antigen expression
43. Immune regulation in Epstein-Barr virus-associated diseases
44. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory
45. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class-I restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4
46. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro
47. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: Implications for sites of viral latency
48. Detection of multiple Epstein-Barr virus strains in allogeneic bone marrow transplant recipients
49. Deletions within the LMP1 oncogene of EBV are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma
50. Non-responsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: Implications for vaccine strategies
51. Lowest dose interleukin-2 immunotherapy
52. HLAA2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2